Phase 3 Study of EBI-005 in Dry Eye Disease

Completed · Phase 3 · Has a placebo group

Conditions studied: Dry Eye Disease (DED)

In brief

This is a phase III double-masked, randomized, controlled study evaluating the efficacy of EBI-005 as compared to vehicle given as a topical ophthalmic solution in each eye to subjects with moderate to severe DED three times daily for 12 weeks. Approximately 730 subjects at up to approximately 50 centers in the United States will be screened, enrolled into the study.

Key facts

Study ID
NCT01998802
Run by
Eleven Biotherapeutics
People needed
670
Starts
2014-01-01
Expected to finish
2015-04-01
Last updated by the study team
2015-06-11

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.